Xilio Therapeutics, Inc. (XLO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 10, 2025, details the results of Xilio Therapeutics, Inc.'s 2025 Annual Meeting of Stockholders. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Waltham, Massachusetts.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
Stockholders approved several key matters at the annual meeting:
- Director Elections: Stockholders elected Renée Russo, Pharm.D., Sara M. Bonstein, and James Shannon, M.D., as Class I directors for three-year terms. All three candidates received significant support, though James Shannon, M.D., received a higher number of withheld votes (1,584,580) compared to the other nominees.
- Authorized Share Increase: Stockholders approved an amendment to increase the total number of authorized common shares from 200,000,000 to 600,000,000. The vote was 38,842,439 for, 1,891,703 against, and 99,082 abstaining.
- Officer Exculpation: Stockholders approved an amendment to the Certificate of Incorporation to reflect Delaware law provisions regarding officer exculpation. The vote was 32,301,484 for, 219,938 against, and 47,118 abstaining.
- Auditor Ratification: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote was 40,708,269 for, 90,955 against, and 34,000 abstaining.
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The primary focus is the administrative completion of the annual meeting votes and the subsequent filing of amendments with the Delaware Secretary of State.
Investor Verification Checklist
- Verify the effective date of the Certificate of Amendment regarding the increase in authorized shares with the Delaware Secretary of State.
- Review the company's most recent 10-K or 10-Q filings for current financial health, cash runway, and operational milestones, as this 8-K contains no financial data.
- Monitor future filings for the issuance of shares from the newly authorized pool of 400 million additional shares.
- Confirm the tenure and specific roles of the newly elected Class I directors (Russo, Bonstein, Shannon) in upcoming proxy statements.